DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

Last updated: April 16, 2025
Sponsor: Barnet Dulaney Perkins Eye Centers
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Treatment

DSLT enables newly diagnosed patients to remain well controlled and off medications

Clinical Study ID

NCT06933836
Alcon - IIT Proposal 95645649
  • Ages > 30
  • All Genders

Study Summary

DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Primary open angle glaucoma

  • Patients age 30 or greater with an IOP of 18-26 mmHg

  • Mild to moderate POAG patients (mild or moderate according to the AAO PPPGuidelines)

  • DSLT procedure

Exclusion

Exclusion Criteria:

  • History of prior glaucoma treatment - this includes past medication use (in eithereye), previous lasers or incisional surgery

  • Angle closure patients

  • Ocular Hypertension

  • Baseline VF MD of worse than -12dB

  • Uncontrolled systemic microvascular disease (eg. HTN, DM)

  • Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium,significant senile arcus and pterygium)

Study Design

Total Participants: 55
Treatment Group(s): 1
Primary Treatment: DSLT enables newly diagnosed patients to remain well controlled and off medications
Phase:
Study Start date:
March 31, 2025
Estimated Completion Date:
December 31, 2027

Study Description

DSLT enables newly diagnosed patients to remain well controlled and off medications

Connect with a study center

  • Barnet Dulaney Perkins Eye Centers

    Mesa, Arizona 85206
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.